HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024

HRMY 10.16.2024

Full Press ReleaseSEC FilingsOur HRMY Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
  • 12.18.2024 - HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Recent Filings

  • 01.21.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.21.2025 - 144 Report of proposed sale of securities
  • 01.13.2025 - 8-K Current report

PLYMOUTH MEETING, Pa.,Oct. 16, 2024/PRNewswire/ --Harmony Biosciences Holdings, Inc.(Nasdaq: HRMY) today announced that it will report third quarter 2024 financial results onTuesday, October 29, 2024, before the open of theU.S.financial markets. Harmony will host a conference call and webcast onOctober 29, 2024, at8:30 a.m. ETto discuss the results.

Harmony Biosciences logo (PRNewsfoto/Harmony Biosciences)

To participate in the call, please dial (800) 245-3047 (domestic) or (203) 518-9765 (international), and reference passcode HRMYQ324. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replay webcast of the call will be available on the investor page of our website athttps://ir.harmonybiosciences.com/.

AboutHarmony BiosciencesHarmony Biosciencesis a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked,Harmony Biosciencesis nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established byParagon Biosciences, LLC, in 2017 and headquartered inPlymouth Meeting, PA, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visitwww.harmonybiosciences.com.

Harmony Biosciences Investor Contact:Brennan Doyle484-539-9700bdoyle@harmonybiosciences.com

Harmony Biosciences Media Contact:Cate McCanless202-641-6086cmccanless@harmonybiosciences.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-report-third-quarter-2024-financial-results-on-october-29-2024-302277106.html

SOURCEHarmony Biosciences

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com